Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company's product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma. Its preclinical programs include FPA150, FPA154 and FPT155.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:FPRX
- CUSIP: N/A
- Web: www.fiveprime.com
Capitalization:- Market Cap: $1 billion
- Outstanding Shares: 27,985,000
Average Prices:- 50 Day Moving Avg: $31.18
- 200 Day Moving Avg: $32.04
- 52 Week Range: $25.97 - $60.98
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -8.12
- P/E Growth: 0.12
Sales & Book Value:- Annual Revenue: $32.9 million
- Price / Sales: 30.40
- Book Value: $11.55 per share
- Price / Book: 3.09
Profitability:- EBIDTA: ($133,090,000.00)
- Net Margins: -356.39%
- Return on Equity: -31.78%
- Return on Assets: -27.55%
Debt:- Current Ratio: 10.22%
- Quick Ratio: 10.22%
Misc:- Average Volume: 269,661 shs.
- Beta: 4.16
- Short Ratio: 9.68
Frequently Asked Questions for Five Prime Therapeutics (NASDAQ:FPRX)
What is Five Prime Therapeutics' stock symbol?
Five Prime Therapeutics trades on the NASDAQ under the ticker symbol "FPRX."
How were Five Prime Therapeutics' earnings last quarter?
Five Prime Therapeutics, Inc. (NASDAQ:FPRX) announced its quarterly earnings results on Tuesday, August, 8th. The company reported ($1.58) EPS for the quarter, missing analysts' consensus estimates of ($1.15) by $0.43. The firm earned $7.80 million during the quarter, compared to analyst estimates of $8.32 million. Five Prime Therapeutics had a negative net margin of 356.39% and a negative return on equity of 31.78%. The business's revenue was down 16.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.49) EPS. View Five Prime Therapeutics' Earnings History.
Where is Five Prime Therapeutics' stock going? Where will Five Prime Therapeutics' stock price be in 2017?
7 brokerages have issued 12 month price targets for Five Prime Therapeutics' stock. Their predictions range from $41.00 to $94.00. On average, they anticipate Five Prime Therapeutics' share price to reach $61.20 in the next year. View Analyst Ratings for Five Prime Therapeutics.
What are analysts saying about Five Prime Therapeutics stock?
Here are some recent quotes from research analysts about Five Prime Therapeutics stock:
- 1. Jefferies Group LLC analysts commented, "Near-term focus is on initial Ph2 data for cabiralizumab in PVNS at ASCO. Roche’s emactuzumab in PVNS showed an ~80% RR at high dose, but resulting in 2 cases of lupus per FPRX." (5/5/2017)
- 2. According to Zacks Investment Research, "Five Prime Therapeutics, Inc. is a biotechnology company. The company focuses on the discovery and development of protein therapeutics that blocks cancer and inflammatory disease processes. It operates primarily in the United States and Canada. Five Prime Therapeutics, Inc. is based in San Francisco, California. " (5/2/2017)
- 3. Cowen and Company analysts commented, "We believe Five Prime has amongst the leading IO drug discovery platforms in the industry. The BMS partnership provides validation. Multiple clinical readouts in 2017 provide catalysts to drive value generation. Lead asset Cabira has significant potential in solid tumors, we expect FPA144 to succeed in FGFR2b+ gastric cancer (2019), and we see high POS for Cabira in PVNS. Initiating at Outperform." (3/24/2017)
- 4. Instinet analysts commented, "We are initiating on Five Prime Therapeutics (FPRX) with a Buy rating and a $94, 12-month target price. We recommend owning FPRX shares ahead of potentially transformational mid-2017 readouts. We anticipate 2017 data from cabiralizumab and key competitors will further de-risk cabiralizumab's anti-CSF1R mechanism in immuno-oncology, define pivotal clinical paths, establish initial market opportunities, and differentiate its safety versus competitors." (3/1/2017)
Who are some of Five Prime Therapeutics' key competitors?
Some companies that are related to Five Prime Therapeutics include Array BioPharma (ARRY), Aerie Pharmaceuticals (AERI), NovoCure Limited (NVCR), Insmed (INSM), MyoKardia (MYOK), Radius Health (RDUS), Acceleron Pharma (XLRN), Lexicon Pharmaceuticals (LXRX), Sangamo Therapeutics (SGMO), Clinigen Group PLC (CLIN), Dynavax Technologies Corporation (DVAX), Dermira (DERM), Acorda Therapeutics (ACOR), Epizyme (EPZM), Xencor (XNCR), Athenex (ATNX), NeuroDerm (NDRM) and Ascendis Pharma A/S (ASND).
Who are Five Prime Therapeutics' key executives?
Five Prime Therapeutics' management team includes the folowing people:
- Lewis T. Williams M.D. Ph.D., Chairman of the Board, President, Chief Executive Officer
- Marc L. Belsky, Chief Financial Officer, Senior Vice President
- Aron Marc Knickerbocker MBA, Chief Operating Officer, Director
- Kevin Baker Ph.D., Senior Vice President, Development Sciences
- Helen Louise Collins M.D., Senior Vice President and Chief Medical Officer
- Francis Willard Sarena J.D., Chief Strategy Officer and Secretary
- Mark D. McDade, Lead Independent Director
- Garry Nicholson, Director
- Franklin M. Berger, Independent Director
- Fred E. Cohen Ph.D. M.D., Independent Director
Who owns Five Prime Therapeutics stock?
Five Prime Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (15.48%), Vanguard Group Inc. (5.93%), State Street Corp (4.84%), Dimensional Fund Advisors LP (3.19%), BB Biotech AG (2.79%) and Victory Capital Management Inc. (2.39%). Company insiders that own Five Prime Therapeutics stock include Adage Capital Partners Gp Llc, Francis Willard Sarena, Franklin M Berger, Lewis T Williams, Marc Belsky, Peder Jensen and William R Ringo. View Institutional Ownership Trends for Five Prime Therapeutics.
Who sold Five Prime Therapeutics stock? Who is selling Five Prime Therapeutics stock?
Five Prime Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Capital Fund Management S.A., Alliancebernstein L.P., Russell Investments Group Ltd., TIAA CREF Investment Management LLC, Dimensional Fund Advisors LP, Renaissance Technologies LLC, OxFORD Asset Management LLP and FMR LLC. Company insiders that have sold Five Prime Therapeutics stock in the last year include Francis Willard Sarena, Lewis T Williams, Peder Jensen and William R Ringo. View Insider Buying and Selling for Five Prime Therapeutics.
Who bought Five Prime Therapeutics stock? Who is buying Five Prime Therapeutics stock?
Five Prime Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Artal Group S.A., Victory Capital Management Inc., DekaBank Deutsche Girozentrale, State Street Corp, Pictet Asset Management Ltd., Williams Jones & Associates LLC and Marshall Wace North America L.P.. View Insider Buying and Selling for Five Prime Therapeutics.
How do I buy Five Prime Therapeutics stock?
Shares of Five Prime Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Five Prime Therapeutics' stock price today?
One share of Five Prime Therapeutics stock can currently be purchased for approximately $35.74.
MarketBeat Community Rating for Five Prime Therapeutics (NASDAQ FPRX)MarketBeat's community ratings are surveys of what our community members think about Five Prime Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Five Prime Therapeutics (NASDAQ:FPRX) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 7 Buy Ratings |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $61.20 (71.24% upside) |
Analysts' Ratings History for Five Prime Therapeutics (NASDAQ:FPRX)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/14/2017 | Royal Bank Of Canada | Initiated Coverage | Outperform -> Outperform | $41.00 | High |  |
| 9/12/2017 | Jefferies Group LLC | Reiterated Rating | Buy | $52.00 | High | |
| 3/24/2017 | Cowen and Company | Initiated Coverage | Outperform | | High | |
| 3/1/2017 | Instinet | Initiated Coverage | Buy -> Buy | $94.00 | N/A | |
| 3/1/2017 | Nomura | Initiated Coverage | Buy | | N/A | |
| 11/7/2016 | Credit Suisse Group | Reiterated Rating | Buy | $54.00 | N/A | |
| 10/25/2016 | Citigroup Inc. | Initiated Coverage | Buy | $65.00 | N/A | |
| 8/8/2016 | Leerink Swann | Reiterated Rating | Outperform | $45.00 -> $58.00 | N/A | |
| 5/19/2016 | Oppenheimer Holdings, Inc. | Reiterated Rating | Outperform | $48.00 | N/A | |
| 4/12/2016 | BMO Capital Markets | Initiated Coverage | Market Perform | $50.00 | N/A | |
| 12/4/2015 | Wells Fargo & Company | Reiterated Rating | Outperform | | N/A | |
(Data available from 9/21/2015 forward)
Earnings History for Five Prime Therapeutics (NASDAQ:FPRX)Earnings History by Quarter for Five Prime Therapeutics (NASDAQ FPRX)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/8/2017 | Q2 2017 | ($1.15) | ($1.58) | $8.32 million | $7.80 million | View | Listen | |
| 5/4/2017 | Q1 2017 | ($0.96) | ($1.21) | $6.05 million | $10.13 million | View | Listen | |
| 2/23/2017 | Q4 2016 | ($0.57) | ($0.73) | $7.09 million | $8.30 million | View | N/A | |
| 11/3/2016 | Q3 | ($0.51) | ($0.72) | $7.50 million | $6.70 million | View | N/A | |
| 8/4/2016 | Q2 | ($0.56) | ($0.49) | $6.38 million | $9.23 million | View | N/A | |
| 5/5/2016 | Q1 | ($0.71) | ($0.49) | $5.26 million | $6.50 million | View | N/A | |
| 3/10/2016 | Q4 | $9.67 | $10.63 | $354.16 million | $363.34 million | View | Listen | |
| 11/4/2015 | Q315 | ($0.99) | ($0.93) | $4.90 million | $5.90 million | View | N/A | |
| 8/6/2015 | Q215 | ($0.44) | ($0.45) | $6.92 million | $6.30 million | View | N/A | |
| 5/13/2015 | Q1 | ($0.46) | ($0.44) | $4.77 million | $4.30 million | View | Listen | |
| 3/17/2015 | Q414 | ($0.40) | ($0.55) | $5.39 million | $4.65 million | View | N/A | |
| 11/10/2014 | Q3 2014 | ($0.40) | ($0.33) | $5.22 million | $6.06 million | View | N/A | |
| 8/5/2014 | Q2 14 | ($0.27) | ($0.46) | $5.39 million | $4.98 million | View | N/A | |
| 3/25/2014 | Q4 | ($0.40) | ($0.43) | $1.52 million | $3.79 million | View | Listen | |
| 11/12/2013 | | ($0.57) | ($2.74) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Five Prime Therapeutics (NASDAQ:FPRX)2017 EPS Consensus Estimate: ($4.86)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.97) | ($0.97) | ($0.97) |
| Q2 2017 | 1 | ($1.03) | ($1.03) | ($1.03) |
| Q3 2017 | 2 | ($1.50) | ($1.34) | ($1.42) |
| Q4 2017 | 2 | ($1.54) | ($1.34) | ($1.44) |
(Data provided by Zacks Investment Research)
Dividend History for Five Prime Therapeutics (NASDAQ:FPRX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Five Prime Therapeutics (NASDAQ:FPRX)Insider Ownership Percentage: 6.50%
Institutional Ownership Percentage: 84.05%
Insider Trades by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 3/1/2017 | William R Ringo | Director | Sell | 500 | $46.73 | $23,365.00 | |
| 2/1/2017 | William R Ringo | Director | Sell | 500 | $46.17 | $23,085.00 | |
| 1/18/2017 | Francis Willard Sarena | Insider | Sell | 3,636 | $47.39 | $172,310.04 | |
| 1/3/2017 | William R Ringo | Director | Sell | 500 | $51.07 | $25,535.00 | |
| 12/23/2016 | Lewis T Williams | CEO | Sell | 30,000 | $50.50 | $1,515,000.00 | |
| 12/1/2016 | William R Ringo | Director | Sell | 500 | $57.72 | $28,860.00 | |
| 11/28/2016 | Francis Willard Sarena | Insider | Sell | 1,710 | $60.14 | $102,839.40 | |
| 11/25/2016 | Francis Willard Sarena | Insider | Sell | 34,654 | $60.38 | $2,092,408.52 | |
| 11/9/2016 | Peder Jensen | Director | Sell | 8,130 | $55.30 | $449,589.00 | |
| 11/1/2016 | William R Ringo | Director | Sell | 500 | $48.67 | $24,335.00 | |
| 10/3/2016 | William R Ringo | Director | Sell | 500 | $52.00 | $26,000.00 | |
| 9/1/2016 | William R Ringo | Director | Sell | 500 | $44.20 | $22,100.00 | |
| 8/1/2016 | William R Ringo | Director | Sell | 500 | $50.77 | $25,385.00 | |
| 7/27/2016 | Peder Jensen | Director | Sell | 12,195 | $49.50 | $603,652.50 | |
| 4/22/2016 | Franklin M Berger | Director | Buy | 5,000 | $49.47 | $247,350.00 | |
| 4/22/2016 | Marc Belsky | CFO | Sell | 34,102 | $50.00 | $1,705,100.00 | |
| 4/21/2016 | Lewis T Williams | CEO | Sell | 48,671 | $48.05 | $2,338,641.55 | |
| 4/19/2016 | Franklin M Berger | Director | Buy | 6,090 | $47.06 | $286,595.40 | |
| 4/15/2016 | Lewis T Williams | CEO | Sell | 1,405 | $48.00 | $67,440.00 | |
| 4/14/2016 | Lewis T Williams | CEO | Sell | 2,725 | $48.00 | $130,800.00 | |
| 4/6/2016 | Lewis T Williams | CEO | Sell | 52,801 | $43.09 | $2,275,195.09 | |
| 4/6/2016 | Marc Belsky | CFO | Sell | 20,814 | $45.04 | $937,462.56 | |
| 3/30/2016 | Francis Willard Sarena | EVP | Sell | 10,000 | $40.01 | $400,100.00 | |
| 3/30/2016 | Lewis T Williams | CEO | Sell | 23,259 | $40.02 | $930,825.18 | |
| 3/30/2016 | Marc Belsky | CFO | Sell | 13,876 | $40.01 | $555,178.76 | |
| 3/2/2016 | Lewis T Williams | CEO | Sell | 23,259 | $36.01 | $837,556.59 | |
| 2/4/2016 | Lewis T. Williams | CEO | Sell | 71,229 | $33.35 | $2,375,487.15 | |
| 1/27/2016 | Francis Willard Sarena | EVP | Sell | 30,000 | $35.22 | $1,056,600.00 | |
| 10/15/2015 | Adage Capital Partners Gp Llc | Major Shareholder | Sell | 125,000 | $27.75 | $3,468,750.00 | |
| 10/15/2015 | Lewis T. Williams | CEO | Sell | 72,352 | $27.24 | $1,970,868.48 | |
| 9/21/2015 | Lewis T Williams | CEO | Sell | 2,648 | $22.06 | $58,414.88 | |
| 6/22/2015 | Lewis T Williams | CEO | Sell | 75,000 | $24.67 | $1,850,250.00 | |
| 1/28/2015 | Franklin M Berger | Director | Buy | 25,000 | $27.03 | $675,750.00 | |
| 1/15/2015 | Franklin M Berger | Director | Buy | 10,049 | $26.17 | $262,982.33 | |
| 11/28/2014 | Franklin M Berger | Director | Buy | 1,951 | $21.04 | $41,049.04 | |
| 11/4/2014 | Lewis T Williams | CEO | Sell | 32,603 | $13.08 | $426,447.24 | |
| 10/30/2014 | Lewis T Williams | CEO | Sell | 17,397 | $13.13 | $228,422.61 | |
| 9/23/2013 | Brian G Atwood | Director | Buy | 76,923 | $13.00 | $999,999.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Five Prime Therapeutics (NASDAQ:FPRX)
Latest Headlines for Five Prime Therapeutics (NASDAQ:FPRX)
| Source: |
|
| Date | Headline |
|---|
 | Five Prime Therapeutics (FPRX) and Its Peers Critical Review
www.americanbankingnews.com - September 19 at 2:30 PM |
| Contrasting Five Prime Therapeutics (FPRX) & Dermira (DERM)
www.americanbankingnews.com - September 17 at 10:16 AM |
 | Five Prime Therapeutics (FPRX) Announces Licensing Agreement ... - StreetInsider.com
www.streetinsider.com - September 15 at 12:27 AM |
| Five Prime Therapeutics, Inc. (FPRX) Receives New Coverage from Analysts at Royal Bank Of Canada
www.americanbankingnews.com - September 14 at 10:36 PM |
 | Ablexis Announces Licensing of the AlivaMab Mouse to Five Prime Therapeutics
globenewswire.com - September 14 at 7:26 PM |
| Five Prime Therapeutics (FPRX) Reports Preclinical Research Data on Novel B7-H4 Therapeutic Antibody at ESMO 2017
www.streetinsider.com - September 12 at 12:25 AM |
 | Array BioPharma And Others Shine At ESMO 2017 Congress ... - Benzinga
www.benzinga.com - September 11 at 7:22 PM |
| Five Prime Therapeutics (FPRX) Reports Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP ... - StreetInsider.com
www.streetinsider.com - September 11 at 7:22 PM |
| Five Prime Therapeutics (FPRX) Reports Preclinical Research Data on Novel B7-H4 Therapeutic Antibody at ESMO 2017 - StreetInsider.com
www.streetinsider.com - September 11 at 7:22 PM |
| Analysts Expect Five Prime Therapeutics, Inc. (FPRX) to Announce -$1.32 EPS
www.americanbankingnews.com - September 11 at 2:16 PM |
 | Five Prime Announces Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039 at ESMO ... - Nasdaq
www.nasdaq.com - September 10 at 5:57 PM |
| Five Prime Presents Preclinical Research Data on Novel B7-H4 Therapeutic Antibody at ESMO 2017 Congress - GlobeNewswire (press release)
globenewswire.com - September 10 at 5:57 PM |
 | Five Prime Announces Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039 at ESMO 2017 Congress
finance.yahoo.com - September 10 at 5:57 PM |
| Five Prime Presents Preclinical Research Data on Novel B7-H4 Therapeutic Antibody at ESMO 2017 Congress
finance.yahoo.com - September 10 at 5:57 PM |
| Five Prime Therapeutics, Inc. (FPRX) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - September 5 at 9:26 PM |
| Five Prime Therapeutics, Inc. (FPRX) Upgraded by ValuEngine to Sell
www.americanbankingnews.com - September 3 at 12:14 PM |
| Five Prime Therapeutics (FPRX) Announces Abstract with Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039 at ESMO
www.streetinsider.com - September 2 at 12:11 AM |
| Five Prime Therapeutics (FPRX) Announces Abstract with Updated Data in Mesothelioma Patients from Ongoing ... - StreetInsider.com
www.streetinsider.com - September 1 at 7:10 PM |
| Five Prime Announces Abstract with Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039 at ESMO 2017 Congress
finance.yahoo.com - September 1 at 7:10 PM |
| Five Prime to Feature Two Oral Data Presentations at ESMO 2017 Congress - Nasdaq
www.nasdaq.com - August 30 at 12:22 AM |
| Five Prime Therapeutics, Inc. – Value Analysis (NASDAQ:FPRX) : August 30, 2017
finance.yahoo.com - August 30 at 12:22 AM |
| Five Prime to Feature Two Oral Data Presentations at ESMO 2017 Congress
finance.yahoo.com - August 29 at 7:18 PM |
| Five Prime Therapeutics (FPRX) to End GITR License Agreement with Inhibrx - StreetInsider.com
www.streetinsider.com - August 29 at 4:35 AM |
| Five Prime Therapeutics (FPRX) to End GITR License Agreement with Inhibrx
www.streetinsider.com - August 28 at 6:32 PM |
| Zacks: Analysts Anticipate Five Prime Therapeutics, Inc. (FPRX) Will Announce Quarterly Sales of $9.00 Million
www.americanbankingnews.com - August 25 at 4:28 AM |
| Five Prime Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : FPRX-US : August 23, 2017
finance.yahoo.com - August 24 at 2:37 AM |
| Analysts Anticipate Five Prime Therapeutics, Inc. (FPRX) Will Announce Earnings of -$1.32 Per Share
www.americanbankingnews.com - August 24 at 12:18 AM |
| Noteworthy Friday Option Activity: FPRX, LULU, GOOGL
www.nasdaq.com - August 18 at 6:42 PM |
| Five Prime Therapeutics Announces Addition of Bryan Irving, PhD, as Senior Vice President, Research - GlobeNewswire (press release)
globenewswire.com - August 17 at 8:03 PM |
| Five Prime Therapeutics Announces Addition of Bryan Irving, PhD, as Senior Vice President, Research
finance.yahoo.com - August 17 at 8:03 PM |
| See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.
finance.yahoo.com - August 14 at 7:09 PM |
| Five Prime Therapeutics, Inc. (FPRX) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - August 11 at 9:06 PM |
| Leerink Swann Equities Analysts Reduce Earnings Estimates for Five Prime Therapeutics, Inc. (FPRX)
www.americanbankingnews.com - August 11 at 9:12 AM |
| Five Prime Therapeutics, Inc. to Post Q3 2017 Earnings of ($1.50) Per Share, Jefferies Group Forecasts (FPRX)
www.americanbankingnews.com - August 11 at 9:12 AM |
| Five Prime Therapeutics, Inc. (FPRX) Stock Rating Reaffirmed by Jefferies Group LLC
www.americanbankingnews.com - August 10 at 12:47 PM |
| Five Prime Therapeutics, Inc. (FPRX) Announces Earnings Results
www.americanbankingnews.com - August 9 at 10:05 PM |
 | Five Prime Therapeutics, Inc. 2017 Q2 - Results - Earnings Call Slides
seekingalpha.com - August 9 at 6:58 PM |
| Edited Transcript of FPRX earnings conference call or presentation 8-Aug-17 8:30pm GMT
finance.yahoo.com - August 9 at 6:58 PM |
| Five Prime Therapeutics' (FPRX) CEO Rusty Williams on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 9 at 4:33 AM |
| Five Prime Therapeutics posts 2Q loss
finance.yahoo.com - August 8 at 11:32 PM |
| Five Prime Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : FPRX-US : August 8, 2017
finance.yahoo.com - August 8 at 6:31 PM |
| Five Prime Announces Second Quarter 2017 Results and Provides Business Update
finance.yahoo.com - August 8 at 6:31 PM |
| Analysts Expect Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Will Announce Quarterly Sales of $10.15 Million
www.americanbankingnews.com - August 7 at 7:06 AM |
| Analysts Expect Five Prime Therapeutics, Inc. (FPRX) to Post -$1.18 EPS
www.americanbankingnews.com - August 5 at 6:30 PM |
| Five Prime Therapeutics to Announce Second Quarter 2017 Financial Results and Host Conference Call on August 8
finance.yahoo.com - July 26 at 7:20 PM |
| Five Prime Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : FPRX-US : July 24, 2017
finance.yahoo.com - July 24 at 9:25 AM |
| Five Prime Therapeutics Initiates Patient Dosing in Phase 1 Clinical Safety ...
www.nasdaq.com - July 18 at 12:42 AM |
| Five Prime Therapeutics, Inc. (FPRX) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - July 17 at 8:52 PM |
| Five Prime Therapeutics (FPRX) Commences Patient Dosing in Phase 1 Clinical Safety Trial Evaluating FPA144 in ... - StreetInsider.com
www.streetinsider.com - July 17 at 7:41 PM |
| Five Prime Therapeutics Initiates Patient Dosing in Phase 1 Clinical Safety Trial Evaluating FPA144 in Gastric Cancer in Japan in Preparation for Future Global Late-Stage Development
finance.yahoo.com - July 17 at 7:41 PM |
Five Prime Therapeutics (FPRX) Chart for Thursday, September, 21, 2017
